# Table of Contents

About MDS

- Purpose, Mission and Goals .......................................................... 1
- MDS Officers (2017-2019) ............................................................. 1
- MDS International Executive Committee ..................................... 2
- International Congress Oversight Committee .......................... 2
- Congress Local Organizing Committee ....................................... 2
- Congress Scientific Program Committee ................................. 2
- Past-Presidents ........................................................................... 2
- International Medical Society For Motor Disturbances Past-Presidents ................................................................. 2
- MDS International Secretariat .................................................... 2

International Congress Information ........................................... 3

- Abstract Poster Information ....................................................... 3
- Exhibition .................................................................................... 3
- Official Language ....................................................................... 3
- Photography Policy .................................................................... 3
- Registration ............................................................................... 3
- Special Accessibility Needs ....................................................... 3
- Venue ......................................................................................... 3

International Congress Events .................................................. 4

- International Congress Schedule-at-a-Glance ............................ 5
- International Congress Session Definitions .............................. 6

Scientific Program ........................................................................ 7

- Sunday, September 22, 2019 ...................................................... 7
- Monday, September 23, 2019 ..................................................... 8
- Tuesday, September 24, 2019 .................................................... 12
- Wednesday, September 25, 2019 ............................................. 16
- Thursday, September 26, 2019 ................................................. 20
- Non-CME Educational Activities .............................................. 21

Faculty Listing ............................................................................. 22

CME Information ......................................................................... 25

Acknowledgements ...................................................................... 26
About MDS

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.

Purpose, Mission and Goals

Purpose:
The objective and mission of the Society shall be to advance the neurological sciences pertaining to movement disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

Mission and Goals:
To disseminate knowledge about movement disorders by:
• Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about movement disorders
• Sponsoring International Congresses and symposia on movement disorders
• Collaborating with other international organizations and lay groups
• Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of movement disorders by:
• Using the Society’s influence and resources to enhance support for research
• Facilitating the dissemination of information about research
• Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

For the purposes of favorably affecting the care of patients with movement disorders, the Society will provide expertise, advice and guidance to:
• Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
• The public (media) and patient support groups by informing them of new research and therapeutic advances
• Governments to assist them in the development of policies that affect support of research and patient care
• Educational efforts to assist in developing standards of training in the specialty

MDS Officers (2017-2019)

President
Christopher Goetz, USA

President-Elect
Claudia Trenkwalder, Germany

Secretary
Susan Fox, Canada

Secretary-Elect
Bastiaan Bloem, Netherlands

Treasurer
Victor Fung, Australia

Treasurer-Elect
Louis Tan, Singapore

Past-President
Oscar Gershanik, Argentina
About MDS

MDS International Executive Committee
Charles Adler, USA
Daniela Berg, Germany
Shengdi Chen, People’s Republic of China
Carlos Cosentino, Peru
Joaquim Ferreira, Portugal
Jeffrey Kordower, USA
Mayela Rodriguez Violante, Mexico
D. James Surmeier, USA
Pille Taba, Estonia
Ryosuke Takahashi, Japan

International Congress Oversight Committee
Chair: Matthew Stern, USA
Jean-Christophe Corvol, France
Günther Deuschl, Germany
Victor Fung, Australia
Oscar Gershanik, Argentina
Christopher Goetz, USA
Hyder Jinnah, USA
Claudia Trenkwalder, Germany

Congress Local Organizing Committee
Chair: Jean-Christophe Corvol
Philippe Damier
Luc Defebvre
Franck Durif
Alexandra Durr
Caroline Giordana
Wassilios Meissner
Elena Moro
Olivier Rascol
Christine Tranchant
Marie Vidailhet

Congress Scientific Program Committee
Chair: Hyder Jinnah, USA
Co-Chair: Jean-Christophe Corvol, France
Roongroj Bhidayasiri, Thailand
Vincenzo Bonifati, Netherlands
M. Angela Cenci Nilsson, Sweden
Shengdi Chen, People’s Republic of China
Steven Frucht, USA
Emilia Gatto, Argentina
Christopher Goetz, USA
Jennifer Goldman, USA
Etienne Hirsch, France
Roland Dominic Jamora, Philippines
Beomseok Jeon, South Korea
Han-Joon Kim, South Korea
Vladimir Kostic, Serbia
Shen-Yang Lim, Malaysia
Irene Litvan, USA
Karen Marder, USA
Wassilios Meissner, France
Vincent Mok, Hong Kong
Elena Moro, France
Alice Nieuwboer, Belgium
Maria Stamelou, Greece
Matthew Stern, USA
Antonio Strafella, Canada
Carolyn Sue, Australia
Ryosuke Takahashi, Japan
Helio Teive, Brazil
Claudia Trenkwalder, Germany

Past-Presidents
2015-2017 Oscar Gershanik, Argentina
2013-2015 Matthew Stern, USA
2011-2013 Günther Deuschl, Germany
2009-2011 Philip Thompson, Australia
2007-2009 Anthony Lang, Canada
2005-2006 Andrew Lees, United Kingdom
2003-2004 C. Warren Olanow, USA
2001-2002 Werner Poewe, Austria
1999-2000 Mark Hallett, USA
1997-1998 Eduardo Tolosa, Spain
1995-1996 Joseph Jankovic, USA
1991-1994 C. David Marsden, United Kingdom
1988-1991 Stanley Fahn, USA

International Medical Society For Motor Disturbances Past-Presidents
1993-1994 C. Warren Olanow, USA
1991-1992 Bastian Conrad, Germany
1989-1990 Mark Hallett, USA
1987-1988 Mario Manfredi, Italy
1985-1986 C. David Marsden, United Kingdom

MDS International Secretariat
International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
E-mail: info@movementdisorders.org
Website: www.movementdisorders.org
Abstract Poster Information
Poster Sessions will be featured from Monday through Wednesday of the International Congress to ensure delegates are given the opportunity to review as many abstracts as possible. Please visit www.mdscongress.org/Congress/Program---Abstracts.htm for further details and information about Abstracts for the 2019 International Congress.

Exhibition
Manufacturers, distributors and suppliers of products and services for physicians and researchers involved with Movement Disorders are invited to participate in the International Congress exhibition. To receive a copy of the Support Opportunities and Exhibitor Prospectus, please contact the MDS International Secretariat at congress@movementdisorders.org or visit www.mdscongress.org/Congress/Sponsorship---Exhibiting/Prospectus.htm. The exhibition is open to all registered delegates.

Official Language
The official language of the 2019 International Congress is English.

Photography Policy
Photography is not permitted in any of the 2019 International Congress scientific and/or educational sessions or in the poster areas.

Registration
Please visit www.mdscongress.org/Congress/Registration.htm for details and to register online.

The International Congress registration fee includes admission to all scientific sessions, Exhibit Hall and Poster Hall and entrance to the Welcome Ceremony and MDS Video Challenge as well as delegate material, a Final Program, the abstracts on USB, a daily morning coffee break and a daily lunch. The registration fee excludes travel and accommodations.

Registration Cancellation/Refund Policy
All cancellations must be requested in writing.
- Up to August 22, 2019 (Final pre-registration deadline): 100% refund, minus a $75 administrative charge
- From August 23 – September 12, 2019: 50% refund
- From September 13, 2019 onward: No refund

Registration Desk
Name badge, scientific session tickets, Final Program and USB with full abstract list can be collected at the International Congress Registration desk in Agora 1 during the following hours**:
Saturday, September 21: 16:00 – 20:00
Sunday, September 22: 7:00 – 20:00
Monday, September 23: 7:00 – 18:00
Tuesday, September 24: 7:00 – 18:00
Wednesday, September 25: 7:00 – 18:00
Thursday, September 26: 7:00 – 12:00

**Please note that these hours are subject to change.

Special Accessibility Needs
Delegates requiring special arrangements in order to fully participate in the International Congress should provide a written description of such needs on their registration form or send an e-mail to congress@movementdisorders.org. To ensure appropriate accommodations, all special needs should be addressed in advance with the MDS International Secretariat.

Venue
Nice Acropolis Convention Centre
1 Esplanade Kennedy 06364
Nice Cedex 4
France
International Congress Events

Saturday, September 21, 2019
NEW! Movement Disorders Awareness 5k Run/Walk: Nice en Mouvement
Join MDS for a Movement Disorders Awareness 5k run/walk at the Promenade des Anglais in Nice, Saturday, September 21, 2019 at 18:00 to benefit La Société Francophone des Mouvements Anormaux (SOFMA). All participants receive a t-shirt and light refreshments at the finish line. If you are interested in participating, you may sign up during the International Congress registration process. Space is limited to 300 delegates, so be sure to register early.

Please note that there is an additional fee for this event.
If you do not plan to run or walk, please consider lining up along the event route to cheer on your colleagues.

The Movement Disorders Awareness 5k Run/Walk is sponsored by Boston Scientific.

Sunday, September 22, 2019
Welcome Ceremony
19:30 – 21:30
All International Congress delegates are warmly invited to attend the International Congress Welcome Ceremony. This event is open to all registered delegates.

Tuesday, September 24, 2019
Young Delegates Networking Event
19:30 – 21:30
MDS invites all registered International Congress delegates to attend the Young Delegates Networking Event. This event will provide an excellent opportunity for delegates who are in the beginning phase of their career to network and socialize with other up-and-coming experts in the field.

The Young Delegates Networking Event is sponsored by Acorda Therapeutics and Medtronic.

Wednesday, September 25, 2019
MDS Video Challenge
19:00 – 22:00
Please join Masters of Ceremony Anthony Lang and Kapil Sethi as they host a world-renowned panel of Movement Disorders experts in guiding participants through unique Movement Disorder cases. The cases will be presented by representatives from Movement Disorder Centers around the world and discussed by the Panel of Experts. Awards will be given for the most interesting and challenging cases. Country pride will add an enjoyable spirit of competition to this event. The goal of this session is for delegates to learn from a series of unusual, very interesting patients and see how senior experts approach these types of challenging cases.

The Panel of Experts:
Stewart Factor, USA
Manju Kurian, United Kingdom
Tiago Mestre, Canada
Francesca Morgante, United Kingdom
Martin Paucar Arce, Sweden

This event is open to all registered delegates. For more information about the MDS Video Challenge, please contact The MDS International Secretariat at congress@movementdisorders.org.

The MDS Video Challenge is sponsored by Boston Scientific.
## International Congress Schedule-at-a-Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Sunday, September 22</th>
<th>Monday, September 23</th>
<th>Tuesday, September 24</th>
<th>Wednesday, September 25</th>
<th>Thursday, September 26</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Therapeutic Plenary Session 8:00 - 10:00</td>
<td>Plenary Session (Presidential Lectures) 8:00 - 10:00</td>
<td>Plenary Session 8:00 - 9:30</td>
<td>Plenary Session 8:00 - 9:30</td>
<td>Plenary Session 8:00 - 9:30</td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Legend:
- CME Accredited Sessions
- Non-CME Educational Activities
- Corporate Therapeutic Symposia (non-CME)
- MDS Activities
- Events
- Breaks
International Congress Session Definitions

**CME Accredited Sessions**

2019 International Congress Themed Sessions: At each annual International Congress, the Congress Scientific Program Committee (CSPC) selects a theme that is highlighted throughout the meeting. This year’s theme, *Translating the Science of Movement Disorders into Clinical Practice*, will be showcased with international experts serving as faculty. Delegates can elect to attend any or all of these sessions. Themed sessions are designated in the program with 🌟.

Controversies: This Plenary Session is designed to involve all International Congress delegates. Content is prepared to stimulate interest and debate among a panel of experts. Views from several angles will be addressed as discussion of pre-selected “hot” topics will be open for debate among the panelists.

Grand Rounds: In this interactive session, MDS experts will examine both common and rare movement disorder patients. The audience will learn how they formulate diagnoses and manage these interesting and challenging patients.

Parallel Sessions: These concurrent sessions provide an in-depth summary of new clinical and basic research findings, state-of-the-art treatment options, and future strategies on a variety of focused topics within the field of Movement Disorders.

Plenary Sessions: These sessions provide an overview of the latest clinical and basic science research findings and state-of-the-art information relating to topics of broad interest within the field of Movement Disorders.

Skills Workshops: These concurrent sessions provide practical illustrations of clinical or scientific techniques relevant to the field of Movement Disorders through video examples and equipment demonstrations.

NEW! Special Topics in Movement Disorders: These interactive sessions address “hot” topics in science or medicine using a variety of different formats that may include lectures, video presentations, and audience interaction.

Teaching Courses: These educational programs provide up-to-date information focused on a single topic. The sessions highlight both the clinical and basic science of topics of relevance to Movement Disorder specialists. The sessions are unique in providing a syllabus that includes a review of the topic and the presentation slides.

Therapeutic Plenary Sessions: These sessions provide an overview of the latest, state-of-the-art treatment options in the diagnosis and management of Parkinson’s disease and other movement disorders.

Video Sessions: These concurrent sessions focus on video demonstrations to provide an overview of clinical movement disorders.

**Corporate Therapeutic Symposia (non-CME)**

These company-based informational sessions provide delegates with non-CME educational opportunities to learn the latest in therapeutics.

**Non-CME Accredited Educational Activities**

Guided Poster Tours: Guided Poster Tours give small groups of delegates an opportunity to hear discussion on a select group of abstracts in several different topics.

**Poster Sessions**: Poster sessions give each delegate an opportunity to view their colleagues’ posters on the most current research in the field of Movement Disorders. Posters are available for daily viewing and authors are present for 90 minutes to discuss their work and answer questions.

**NEW! Science of Industry Session**: These interactive sessions will provide delegates with a non-CME educational (non-CME) opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate basic scientists or clinicians working in industry, and topics may address the biological rationale or development process for specific therapeutics in development within the field of Movement Disorders.

**International Congress Events**

MDS Video Challenge: The goal of this session is for delegates to learn from a series of unusual patients and observe how senior experts approach a challenging case. A world-renowned panel of Movement Disorders experts guide delegates through unique Movement Disorder cases as they are presented by representatives from Movement Disorder centers around the world.

Welcome Ceremony: All International Congress delegates are warmly invited to attend the Welcome Ceremony at the Nice Acropolis Convention and Exhibition Centre. This event is open to all registered delegates and there is no additional fee to attend.

Young Delegates Networking Event: MDS invites all registered International Congress delegates to attend the Young Delegates Networking Event. This event will provide an excellent opportunity for delegates who are in the beginning phase of their career to network and socialize with other up-and-coming experts in the field.

**MDS Activities**

MDS Business Meeting: Open to all International Congress delegates, the Society encourages Members to attend the MDS Business Meeting to receive updates from the MDS President and other MDS Officers on the Society, the various Regional Sections, to participate in the Officers’ and International Executive Committee (IEC) election and to discuss other Society concerns.

Regional Assemblies: Delegates from each of the various MDS Regional Sections (MDS-AOS, MDS-ES, MDS-PAS, and Africa) are invited to participate in the Regional Assemblies to receive updates on activities and general concerns from within the sections.

**International Congress Faculty Roles**

Chair: Facilitates the learnings of the session; ensures that learning objectives are met during the presentation(s), and engages the learners as needed.

CSPC Liaison: Develops the session from the onset and provides guidance to ensure that the overall objectives are met.

Speaker / Presenter: Creates and delivers the presentation materials, and participates in the dialogue of the session.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Chairs</th>
<th>Liaison</th>
</tr>
</thead>
<tbody>
<tr>
<td>1101</td>
<td>Recognition and Treatment of Early Stage Parkinson’s Disease</td>
<td>8:00 – 10:00</td>
<td>Franck Durif, France, Susan Fox, Canada</td>
<td>Daniela Berg, Germany, Shen-Yang Lim, Malaysia, Olivier Rasol, France</td>
</tr>
<tr>
<td>1102</td>
<td>Recognition and Treatment of Complications in Later Stage Parkinson’s Disease</td>
<td>11:00 – 13:00</td>
<td>Elena Moro, France, Louis Tan, Singapore</td>
<td>Angela Antonini, Italy, Jennifer Goldman, USA, Nir Giladi, Israel</td>
</tr>
<tr>
<td>1103</td>
<td>Diagnosis and Treatment of Atypical Parkinsonian Disorders</td>
<td>14:30 – 16:30</td>
<td>Irene Litvan, USA, Francois Tison, France</td>
<td>Maria Teresa Pellecchia, Italy, Wassilios Meissner, France</td>
</tr>
<tr>
<td>1104</td>
<td>Recognition and Treatment of Dystonia, Tremor and Ataxia</td>
<td>17:00 – 19:00</td>
<td>Antonio Strafella, Canada, Christine Tranchant, France</td>
<td>Elan Louis, USA, Elizabeth Slow, Canada</td>
</tr>
</tbody>
</table>

**2019 International Congress Theme**

At each annual International Congress, the Congress Scientific Program Committee selects a theme that is highlighted throughout the meeting. This year’s theme, *Translating the Science of Movement Disorders into Clinical Practice*, will be showcased in three Plenary Sessions, eleven (11) Parallel Sessions, one Skills Workshop, and one Special Topic Session. International experts will serve as faculty, and the meeting delegates can elect to attend any of these sessions.
## Monday, September 23, 2019

### 2101 Plenary Session

#### Presidential Lectures

8:00 – 10:00

- Chairs: Christopher Goetz, USA
  - Claudia Trenkwalder, Germany
- Stanley Fahn Lecture
- Cynthia Comella, USA
- Junior Award Lectures
  - To Be Announced
- C. David Marsden Lecture
  - Christine Klein, Germany

CSPC Liaison: Buz Jinnah, USA

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

### 2102 Plenary Session

#### Update on Neurosurgical Interventions for Movement Disorders

10:30 – 12:30

- Chairs: Jean-Philippe Azulay, France
  - Stéphane Palfi, France
- Redefining Neurosurgical Indications and Interventions for Movement Disorders
  - Helen Bronte-Stewart, USA
- Lessons Learned and Current Developments in Neuromodulation
  - Maria Fiorella Contarino, Netherlands
- Overview on MRI-Focused Ultrasound
  - Clement Hamani, Canada

CSPC Liaison: Elena Moro, France

At the conclusion of this session, participants should be better able to:
1. Identify signs and appropriate surgical intervention for patients with movement disorders
2. Describe pros and cons of different neuromodulation treatments, including DBS
3. Summarize the latest available knowledge about MRI-focused ultrasound

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

### 2203 Parallel Session

#### Cognitive Issues in Parkinson’s Disease

15:30 – 17:30

- Chairs: Bruno Dubois, France
  - Jennifer Goldman, USA
- Cognitive Impairment: Clinical Phenotype and Heterogeneity
  - Caroline Williams-Gray, United Kingdom
- Neuroimaging Markers of Cognitive Dysfunction
  - Antonio Strafella, Canada
- Management Strategies for Cognitive Issues
  - Irena Rektorova, Czech Republic

CSPC Liaison: Jennifer Goldman, USA

At the conclusion of this session, participants should be better able to:
1. Illustrate the clinical phenotype and heterogeneity associated with cognitive issues in Parkinson’s disease
2. Discuss neuroimaging markers associated with cognitive issues in Parkinson’s disease
3. Review management strategies for cognitive issues in Parkinson’s disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

### 2204 Parallel Session

#### Parkinson’s Disease and Atypical Parkinsonism: Tauopathies vs. Synucleinopathies

15:30 – 17:30

- Chairs: Irene Litvan, USA
  - Maria Stamelou, Greece
- Diagnostic Pearls in Recognizing Tauopathies vs. Synucleinopathies
  - Stephen Reich, USA
- Pathophysiology and Targets for Therapeutic Interventions
  - Lawrence Golbe, USA
- Disease Modifying Therapies
  - Huw Morris, United Kingdom

CSPC Liaison: Irene Litvan, USA

At the conclusion of this session, participants should be better able to:
1. Describe how to distinguish patients with tauopathies from synucleinopathies
2. Summarize the mechanisms leading to the development and spread of tauopathies versus synucleinopathies
3. Describe the biological rationale for experimental therapies

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

### 2205 Science of Industry Session (non-CME)

See page 21 for complete session information.
Monday, September 23, 2019

**2206  Parallel Session**

**Ataxia**
15:30 – 17:30

Chairs: Alexandra Durr, France
Helio Teive, Brazil

The Clinical Approach to Patients with Ataxia
Hidehiro Mizusawa, Japan

From Phenotype to Genotype in Ataxia
Alexandra Durr, France

Ataxia Syndromes in Children and Adults
Ludger Schöels, Germany

CSPC Liaison: Buz Jinnah, USA

At the conclusion of this session, participants should be better able to:
1. Describe the approach for reaching an etiological diagnosis in patients with ataxia
2. Examine the different phenotypes of ataxia in both children and adults
3. Describe the genetic basis for common disorders with ataxia

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

This presentation is offered in collaboration with the European Academy of Neurology.

**2207  Parallel Session**

**Tics and Tourette Syndrome: From Bench to Bedside**
15:30 – 17:30

Chairs: Andreas Hartmann, France
Davide Martino, Canada

Motor and Behavioral Spectrum of Tics and Tourette Syndrome
Christos Ganos, Germany

Pathophysiology of Tics and Tourette Syndrome
Yulia Worbe, France

Pharmacological and Non-Pharmacological Therapy of Tics and Tourette Syndrome
Davide Martino, Canada

CSPC Liaison: Jean-Christophe Corvol, France

At the conclusion of this session, participants should be better able to:
1. Recognize the clinical spectrum (motor and behavioral) of tics and Tourette syndrome
2. Analyze the pathophysiology of tics and Tourette syndrome including both proposed sites of origin and abnormalities of synaptic transmission
3. Adapt the therapeutic approaches tailored to the needs of individual patients with tics and Tourette syndrome

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**2208  Parallel Session**

**Translating the Science of Functional (Psychogenic) Movement Disorders Into Clinical Practice**
15:30 – 17:30

Chairs: Beomseok Jeon, South Korea
Kathrin LaFaver, USA

Connecting Pathophysiology and Risk Factors to Clinical Care in Functional Movement Disorders
Selma Aybek Rusca, Switzerland

Treatment Choices in Functional Movement Disorders: Established and Novel Treatments
Kathrin LaFaver, USA

Putting It Together: How to Develop and Run a Clinical Service for Functional Movement Disorders
Mark Edwards, United Kingdom

CSPC Liaison: Beomseok Jeon, South Korea

At the conclusion of this session, participants should be better able to:
1. Explain the pathophysiology and risk factors of functional movement disorders
2. Discuss the evidence base for physiotherapy and multidisciplinary rehabilitation in functional movement disorders
3. Discuss how to design care pathways and run a service for people with functional movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**2309  Teaching Course**

**Integrated Management of Movement Disorders: The Example of Parkinson’s Disease**
15:30 – 17:30

Chairs: Alice Nieuwboer, Belgium
Mayela Rodriguez Violante, Mexico

How to Organize Multidisciplinary Care
Carsten Eggers, Germany

Physical and Occupational and Speech Therapy
Alice Nieuwboer, Belgium

Shifting Management Towards Patient-Centered Care and Empowerment
Maria Piemonte, Brazil

CSPC Liaison: Wassilios Meissner, France

At the conclusion of this session, participants should be better able to:
1. Describe the organization of a multidisciplinary care team for Parkinson’s disease
2. Apply the evidence for physical, occupational and speech therapy for Parkinson’s disease
3. Discuss strategies to enhance patient-centered care and patient empowerment in patients with Parkinson’s disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

This course will be recorded and developed into an online MDS eLearning module that will be available to MDS Members.
Monday, September 23, 2019

### 2310 Teaching Course

**Using Imaging Methods for Movement Disorders**

15:30 – 17:30

**Chairs:** Han-Joon Kim, South Korea  
Stephane Lehericy, France

**Structural and Functional MRI Imaging**  
Stephane Lehericy, France

**Brain Imaging Using PET and SPECT**  
Jee-Young Lee, South Korea

**Other Novel and Non-CNS Imaging Techniques**  
Thilo Van Eimeren, Germany

CSPC Liaison: Han-Joon Kim, South Korea

At the conclusion of this session, participants should be better able to:

1. Explain the role of MRI techniques in the diagnosis of Parkinson’s disease and other movement disorders
2. Discuss how PET and SPECT imaging can detect brain alterations in Parkinson’s disease and other movement disorders
3. Report the use and limitations of other neuroimaging techniques in Parkinson’s disease and other movement disorders (TCS, NIRS, OCT, and MIBG)

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

This course will be recorded and developed into an online MDS eLearning module that will be available to MDS Members.

### 2411 Skills Workshop

**Advanced Therapies for Movement Disorders: Difficult Cases and Pitfalls**

18:00 – 19:30

Tove Henriksen, Denmark  
Andrea Kühn, Germany

CSPC Liaisons: Elena Monre, France  
Claudia Trenkwalder, Germany

In this interactive session, the presenters will describe the selection process of parkinsonian patients who can benefit from advanced therapies, and how to recognize and manage issues and complications related to these treatments. In particular, cases presenting with infusion therapies such as apomorphine pump and levodopa intestinal infusion, and Deep Brain Stimulation therapy will be discussed.

At the conclusion of this session, participants should be better able to:

1. Describe the selection of patients for the different advanced therapies
2. Recognize and manage problems and side effects during infusion therapies with apomorphine and LDLD
3. Identify and manage the most frequent problems related to neuromodulation surgery and post-surgery management

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

### 2412 Skills Workshop

**Using Genetic Tools for Diagnosis**

18:00 – 19:30

Hui Fang Shang, People’s Republic of China  
Matthias Synofzik, Germany

CSPC Liaison: Vincenzo Bonifati, Netherlands

In this interactive session, the presenters will describe the different tools currently available for the laboratory diagnosis of genetic movement disorders, including tools for the detection of mutations in single genes (including small sequence and copy number variants), as well as gene panels, clinical whole-exome (WES) and whole-genome sequencing (WGS).

At the conclusion of this session, participants should be better able to:

1. Identify currently existing tools for the laboratory diagnosis of genetic movement disorders
2. Recognize the advantages and disadvantages of the different tools
3. Define the strategy of choice for diagnostic genetic testing of patients with movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

### 2413 Skills Workshop

**Metabolic Movement Disorders**

18:00 – 19:30

Jennifer Friedman, USA  
Mayela Rodriguez Violante, Mexico

CSPC Liaison: Maria Stamelou, Greece

In this interactive session, the presenters will discuss the phenotypic spectrum of movement disorders caused by a variety of metabolic diseases, diagnostic tools to approach metabolic movement disorders and available treatment plans for patients with these disorders.

At the conclusion of this session, participants should be better able to:

1. Interpret the phenotypic spectrum of movement disorders caused by metabolic diseases
2. Describe diagnostic tools for metabolic disease causing movement disorders
3. Design, review and modify a treatment plan for patients with metabolic movement disorders

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Monday, September 23, 2019

**2514 Video Session**  
**TICKET**  
**Atypical Parkinsonism**  
18:00 – 19:30  
Gesine Respondek, Germany  
Iva Stankovic, Serbia  
CSPC Liaison: Ryosuke Takahashi, Japan  
In this interactive session, the presenters will explain the clinical diagnostic criteria and red flags for atypical parkinsonism and show videos of the phenomenology of patients with atypical parkinsonism such as progressive supranuclear palsy, corticobasal syndrome, multiple system atrophy and Lewy body disease. The audience will learn important tips to clinically distinguish atypical parkinsonism from Parkinson's disease.  
At the conclusion of this session, participants should be better able to:  
1. Identify the phenotypic spectrum of atypical parkinsonism  
2. Describe clinical clues useful in the diagnosis of atypical parkinsonism  
3. Explain current clinical diagnostic criteria of atypical parkinsonism  
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**2515 Video Session**  
**TICKET**  
**A Case-Based Approached to Dystonia: What Would You Do?**  
18:00 – 19:30  
Susan Bressman, USA  
Joseph Jankovic, USA  
CSPC Liaison: Steven Frucht, USA  
In this interactive session, experienced movement disorders clinicians will use a case-based approach to describe the strategy for diagnosis and treatment of various types of dystonia, both common and rare.  
At the conclusion of this session, participants should be better able to:  
1. Recognize unusual presentations of various forms of dystonia  
2. Explain the differences in opinion of applying modern practical techniques (oral medications, botulinum toxin, Deep Brain Stimulation, rehabilitation therapy) to treatment of a wide variety of forms of dystonia  
3. Evaluate pitfalls in the diagnosis and treatment of dystonia  
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**2616 Special Topics in Movement Disorders**  
**TICKET**  
**The Future Is Now: Telemedicine in Your Movement Disorders Practice**  
18:00 – 19:30  
Esther Cubo Delgado, Spain  
Ali Shalash, Egypt  
CSPC Liaison: Maria Stamelou, Greece  
In this interactive session, the presenters will discuss clinical situations in which telemedicine may be helpful for improving care of patients with movement disorders such as Parkinson's disease and will describe practical ways in which such telemedicine visits can be implemented in everyday clinical practice. The audience will observe and identify the challenges and possible hurdles that need to be overcome for telemedicine visits to be implemented in clinical practice.  
At the conclusion of this session, participants should be better able to:  
1. Detect situations amenable to telemedicine for improving patients' care  
2. Describe ways in which a telemedicine visit can be implemented in clinical practice  
3. Identify challenges in telemedicine visits and ways to overcome them  
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**2617 Special Topics in Movement Disorders**  
**TICKET**  
**Gait Disorders: From Pathophysiology to the Clinic**  
18:00 – 19:30  
Klaus Jahn, Germany  
Jorik Nonnekes, Netherlands  
CSPC Liaison: Alice Nieuwboer, Belgium  
At the conclusion of this session, participants should be better able to:  
1. Translate a systems understanding of gait disorder into the clinical picture  
2. Recognize cerebellar and vestibular contributions to gait disorders and their management  
3. Recognize corticostriatal dysfunction in gait disorders and their management  
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**2618 Special Topics in Movement Disorders**  
**TICKET**  
**Induced Pluripotent Stem Cells (iPS) and Organoids: State-of-the-Art**  
18:00 – 19:30  
Agnete Kirkeby, Denmark  
Wim Mandemakers, Netherlands  
CSPC Liaison: Vincenzo Bonifati, Netherlands  
In this session, the technology of induced pluripotent stem cells (iPS) and brain organoids as powerful tools for disease modeling will be presented, and the potential application of IPS in the experimental therapy of Parkinson's disease will be discussed.  
At the conclusion of this session, participants should be better able to:  
1. Illustrate the application of human induced pluripotent stem cell (iPS) technology and brain organoids to study mechanisms of movement disorders  
2. Discuss the potential of human induced pluripotent stem cell (iPS) technology to treat Parkinson's disease  
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Tuesday, September 24, 2019

3101  Plenary Session

Tremor Disorders: Challenges and Future Directions
8:00 – 9:30
Chairs: Kailash Bhatia, United Kingdom
       Maria Stamelou, Greece
Overview of the New Classification Scheme for Tremor
Rodger Elble, USA
What Do We Know About Etiologies?
Peter Bain, United Kingdom
Pathophysiology of Tremor: Is Pathophysiology Useful in Diagnosis and Classification?
Rick Helmich, Netherlands

CSPC Liaison: Maria Stamelou, Greece
At the conclusion of this session, participants should be better able to:
1. Apply the new tremor classification scheme in everyday clinical practice
2. Describe how the etiologies of tremor relate to classification
3. Describe how the pathophysiology of tremor relates to the diagnosis and classification of tremor
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3102  Plenary Session

Grand Rounds
10:30 – 12:30
MDS Experts:
   Tim Anderson, New Zealand
   Mathieu Anheim, France
   Steven Frucht, USA
   Timothy Lynch, Ireland

CSPC Liaison: Jean-Christophe Corvol, France
In this interactive session, MDS experts will examine both common and complex movement disorder patients. The audience will gain expert advice on how to formulate diagnoses and manage interesting and challenging patients.

At the conclusion of this session, participants should be better able to:
1. Identify how experts use the clinical history and exam to formulate a diagnosis in movement disorder cases
2. Identify how experts use diagnostic testing in the differential diagnosis of movement disorders
3. Identify how experts plan therapies for movement disorder patients
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3203  Parallel Session

Psychosis and Hallucinations in Lewy Body Disorders
15:30 – 17:30
Chairs: Gilles Feneon, France
       Simon Lewis, Australia
Current Theories on Visual Hallucinations
Nico Diederich, Luxembourg
Neuroimaging and Visual Hallucinations: A Window Into Their Mechanism
Simon Lewis, Australia
Management Strategies for Visual Hallucinations and Psychosis
Laura Marsh, USA

CSPC Liaison: Jennifer Goldman, USA
At the conclusion of this session, participants should be better able to:
1. Identify current theories of visual hallucinations in Parkinson’s disease and Lewy body disorders
2. Describe neuroimaging findings associated with visual hallucinations in Parkinson’s disease and Lewy body disorders
3. Review management strategies for hallucinations and delusions in Parkinson’s disease and Lewy body disorders
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3204  Parallel Session

Challenges in Clinicogenetic Correlations: One Gene - Many Phenotypes; One Phenotype - Many Genes
15:30 – 17:30
Chairs: Vincenzo Bonifati, Netherlands
       Enza Maria Valente, Italy
One Gene – Many Phenotypes
Niccolò Mencacci, USA
One Phenotype – Many Genes
Aurélie Meneret, France
Clinical Implications – Diagnosis and Management Strategies
Enza Maria Valente, Italy

CSPC Liaison: Vincenzo Bonifati, Netherlands
At the conclusion of this session, participants should be better able to:
1. Recognize the sometimes different and complex phenotypes of monogenic mutations
2. Describe similar clinical phenotypes resulting from mutations in different genes
3. Discuss the evolving role of genetics in the diagnosis and management of movement disorders
Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees
Tuesday, September 24, 2019

3205 Parallel Session

**Myoclonus**
15:30 – 17:30

Chairs: Marina De Koning-Tijssen, Netherlands
Steven Frucht, USA

- The Essential Role of Physiology in Understanding and Evaluating Myoclonus
  Hiroshi Shibasaki, Japan
- The Progressive Myoclonic Epilepsies - How Genetics Have Revolutionized Understanding of These Disorders
  Pierre Genton, France
- Treatment of Myoclonus: What Is the Evidence?
  Martje Van Egmond, Netherlands

CSPC Liaison: Steven Frucht, USA
At the conclusion of this session, participants should be better able to:
1. Explain the role of physiology in the evaluation and management of myoclonus
2. Appreciate the enormous strides made in understanding genetic forms of myoclonus
3. Review the evidence supporting decisions on treatments for myoclonus

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3206 Parallel Session

**Translational Science of Dystonia**
15:30 – 17:30

Chairs: William Dauer, USA
Marie Vidailhet, France

- How Genetics, Cell Biology and Animal Models Informed Our Understanding of Dystonia
  William Dauer, USA
- Dystonia as a Network Disorder: How Physiology and Imaging Have Informed Our Understanding of Dystonia
  Ryuji Kaji, Japan
- The Mystery of Deep Brain Stimulation in Dystonia: Are We Any Closer to Understanding How it Works?
  Jill Ostrem, USA

CSPC Liaison: Carolyn Sue, Australia
At the conclusion of this session, participants should be better able to:
1. Discuss the role that advances in the basic sciences have played in our understanding of dystonia
2. Summarize the role that imaging and physiology have played in understanding the biological bases for dystonia
3. Analyze the current theories explaining the improvement of dystonia with Deep Brain Stimulation

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3207 Parallel Session

**Drug Repurposing in Parkinson’s Disease**
15:30 – 17:30

Chairs: Wassilios Meissner, France
D. James Surmeier, USA

- Recent and Ongoing Clinical Trials with Repurposed Drugs
  Michael Schwarzschild, USA
- Repurposing Anti-Hypertensive Drugs: Rationale and Clinical Experience
  Tatyana Simuni, USA
- Insulin Resistance and Diabetes: Repurposing Antidiabetics as Disease Modifying Treatments
  Wassilios Meissner, France

CSPC Liaison: Angela Cenci, Sweden
At the conclusion of this session, participants should be better able to:
1. Critically review recent clinical studies for Parkinson’s disease involving inosine, nilotinib, simvastatin, and iron chelators
2. Summarize scientific rationale and clinical study of isradipine for disease modification in Parkinson’s disease
3. Discuss the scientific rationale for repurposing antidiabetics as potential disease-modifying treatments for Parkinson’s disease

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3208 Science of Industry Session (non-CME)

See page 21 for complete session information.

3309 Teaching Course

**Recognition and Management of Sleep Disturbances in Movement Disorders**
15:30 – 17:30

Chairs: Ron Postuma, Canada
Aleksandar Videnovic, USA

- Insomnia and Somnolence in Movement Disorders
  Aleksandar Videnovic, USA
- Restless Legs Syndrome in Movement Disorders
  Juliane Winkelmann, Germany
- Parasomnias and Sleep-Related Breathing Disorders in Movement Disorders
  Ron Postuma, Canada

CSPC Liaison: Wassilios Meissner, France
At the conclusion of this session, participants should be better able to:
1. Discuss the management of insomnia and excessive daytime sleepiness in movement disorders
2. Discuss the management of restless legs syndrome in movement disorders
3. Analyze investigations and therapeutic options for parasomnias and sleep-related breathing disorders in movement disorders

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Tuesday, September 24, 2019

3310 Teaching Course [TICKET]

Pediatric Movement Disorders
15:30 – 17:30

Chairs: Manju Kurian, United Kingdom
Ali Shalash, Egypt

Transient Benign Movement Disorders of Infancy
Emilio Fernández-Alvarez, Spain

Genetic Movement Disorders in Children and Adolescents
Manju Kurian, United Kingdom

Acquired Movement Disorders in Children and Adolescents
Darius Ebrahimi-Fakhari, USA

CSPC Liaison: Wassilios Meissner, France

At the conclusion of this session, participants should be better able to:
1. Recognize transient benign movement disorders in infancy
2. Summarize genetic movement disorders in children and adolescents
3. Illustrate acquired movement disorders in children and adolescents

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

3411 Skills Workshop [TICKET]

Allied Health Professionals’ Skills for Proactive Patient Management
18:00 – 19:30

Terry Ellis, USA
Sue Thomas, United Kingdom

CSPC Liaison: Alice Nieuwboer, Belgium

In this interactive session, the presenters will focus on how to assess and manage Parkinson’s disease patients proactively to maintain optimal levels of subjective well-being. The audience will learn about the benefits of involving nurses and physical therapists in patient care and learn about the timely interventions of each profession to prevent disease-related complications.

At the conclusion of this session, participants should be better able to:
1. Identify the most optimal management strategies to prevent Parkinson’s disease-related complications in various disease stages
2. Define the role of the Parkinson’s disease nurse in realizing proactive patient care
3. Explain methods to enhance exercise compliance and physical activity levels in Parkinson’s disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3412 Skills Workshop [TICKET]

Clinical Applications of Big Data Analytics in Movement Disorders: Challenges, Promises and Potentials
18:00 – 19:30

Jean-Christophe Corvol, France
Charles Venuto, USA

CSPC Liaison: Roongrui Bhidayasiri, Thailand

In this session, the presenters will describe the nascent field of big data analytics in movement disorders, discuss the benefits as well as limitations, outline methodologies and applications on how to integrate small data sets. Examples with clinical applications will be provided (e.g. genetics and imaging). The presenters will briefly discuss challenges and offer recommendations for the future.

At the conclusion of this session, participants should be better able to:
1. Define advantages and challenges of big data analytics in movement disorders
2. Describe architectural framework of big data analytics through the process of application, development, and methodology
3. Evaluate examples of big data analytics in movement disorders (especially Parkinson’s disease) with their clinical applications

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3413 Skills Workshop [TICKET]

Monogenic Hyperkinetic Disorders with Variable Phenotypes
18:00 – 19:30

Martin Paucar Arce, Sweden
Ana Westenberger, Germany

CSPC Liaison: Vincenzo Bonifati, Netherlands

In this interactive session, the presenters will describe the pleomorphic phenotypes associated with ATP1A3, ADCYS5, and PDE10A and other related genes, as well as the underlying genotypes, and they will discuss how these rare monogenic movement disorders might provide insights for understanding normal brain functions and the pathogenesis of more common forms of complex movement disorders.

At the conclusion of this session, participants should be better able to:
1. Discuss disorders associated with mutations in the ATP1A3, ADCYS5, and PDE10A gene variants
2. Illustrate the underlying genetic variants and emerging genotype-phenotype correlations
3. Discuss possible insights deriving from these rare monogenic forms for understanding of normal brain functions and the pathogenesis of more common movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Students/Residents/Trainees
Tuesday, September 24, 2019

3414 Skills Workshop

Eye Movements: A Case-Based Approach
18:00 – 19:30
Vivek Lal, USA
Aasef Shaikh, USA
CSPC Liaison: Roongroj Bhidayasiri, Thailand

In this interactive session, delegates will acquire clinical skills on how to examine ophthalmological, focusing on eye movement examinations, to recognize typical abnormalities and to integrate these findings into a differential diagnosis of movement disorder conditions.

At the conclusion of this session, participants should be better able to:
1. Describe the approach to a bedside neuro-ophthalmological exam in movement disorders
2. Recognize typical eye movement abnormalities in common hypokinetic and hyperkinetic disorders
3. Integrate findings from bedside ophthalmological examinations into differential diagnosis of movement disorders

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3516 Video Session

Movement Disorder Emergencies
18:00 – 19:30
Roongroj Bhidayasiri, Thailand
Anna Castrioto, France
CSPC Liaison: Shen-Yang Lim, Malaysia

In this interactive session, the presenters will show videos of hypokinetic and hyperkinetic emergencies, and outline the management strategies for these conditions.

At the conclusion of this session, participants should be better able to:
1. Recognize clinical settings and signs of movement disorder emergencies, including emergencies related to Deep Brain Stimulation
2. Explain management strategies for the various Parkinson’s disease related and other hypokinetic emergencies
3. Describe management strategies for the various hyperkinetic emergencies

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3415 Skills Workshop

A Case-Based Approach for Management of Motor Fluctuations and Dyskinesias
18:00 – 19:30
Han-Joon Kim, South Korea
Fabrizio Stocchi, Italy
CSPC Liaison: Maria Stamelou, Greece

In this interactive session, the faculty will describe the clinical phenomenology of both motor fluctuations and dyskinesias in Parkinson’s disease, along with current and potential future treatment strategies.

At the conclusion of this session, participants should be better able to:
1. Describe the various types of motor fluctuations in Parkinson’s disease
2. Describe the various types of dyskinesias in Parkinson’s disease
3. Summarize treatment strategies for motor fluctuation and dyskinesias

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3617 Special Topics in Movement Disorders

Axial Movement Disorders: Camptocormia, Pisa Syndrome, Antecollis, and Retrocollis
18:00 – 19:30
Günter Deuschl, Germany
Michele Tinazzi, Italy
CSPC Liaison: Buz Jinnah, USA

In this session, faculty will describe axial defects in Parkinson’s disease and other movement disorders including their clinical manifestations, pathophysiology and treatment.

At the conclusion of this session, participants should be better able to:
1. Describe the varied clinical manifestations of postural abnormalities in various movement disorders
2. Discuss possible mechanisms of postural problems in various movement disorders
3. Summarize avenues for management of postural problems in various movement disorders

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3618 Special Topics in Movement Disorders

How to Become a Successful Movement Disorder Specialist
18:00 – 19:30
Yves Agid, France
Caroline Tanner, USA
CSPC Liaison: Roland Dominick Jamora, Philippines

In this interactive session, the presenters will discuss the approach to becoming a successful movement disorder specialist in academic and private practice settings.

At the conclusion of this session, participants should be better able to:
1. Recognize the best approach to becoming an excellent movement disorder specialist in academic medicine and in the clinic
2. Recognize the importance of searching for good mentors when pursuing specialization
3. Identify essential aspects of becoming an effective leader

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

Preliminary Program • www.mdscongress.org
Wednesday, September 25, 2019

4101 Plenary Session

Predicting Parkinson’s Disease Onset and Progression
8:00 – 9:30

Chairs: Jean-Christophe Corvol, France
Matthew Stern, USA

What Can Big Cohorts Add to Prediction for Parkinson’s Disease?
Andrew Siderowf, USA

Precision Medicine: Insights from Genetic and Other Biomarkers
Rejko Krueger, Luxembourg

Sleep and Parkinson’s Disease: Prediction and Progression
Friederike Sixel-Doring, Germany

CSPC Liaison: Jean-Christophe Corvol, France

At the conclusion of this session, participants should be better able to:
1. Discuss implications of results from big cohorts in predicting onset or progression of Parkinson’s disease
2. Discuss the role of genetic and other biomarkers in predicting onset or progression of Parkinson’s disease
3. Identify the predictive value of sleep disorders in predicting onset or progression of Parkinson’s disease

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4102 Plenary Session

Autoimmune Movement Disorders: From Phenomenology to Immunopathogenesis
10:00 - 12:00

Chairs: Jerome Honnorat, France
Carolyn Sue, Australia

How Do I Recognize an Autoimmune Movement Disorder?
Sarosh Irani, United Kingdom

The Pathogenesis of Autoimmune Movement Disorders
Angela Vincent, United Kingdom

Therapeutic Approaches to Autoimmune Movement Disorders
Sean Pittock, USA

CSPC Liaison: Carolyn Sue, Australia

At the conclusion of this session, participants should be better able to:
1. Describe the clinical clues for autoimmune movement disorders
2. Explain the molecular mechanisms of autoimmune movement disorders
3. Summarize therapeutic approaches for autoimmune movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4203 Parallel Session

Placebos in Parkinson’s Disease and Other Movement Disorders
15:00 – 17:00

Chairs: Christopher Goetz, USA
Olivier Rascol, France

The Science of Placebo
Fabrizio Benedetti, Italy

Assessing Placebo Response in Clinical Trials
Joaquim Ferreira, Portugal

Harnessing the Power of Placebos in Clinical Practice and Research
Tiago Mestre, Canada

CSPC Liaison: Jean-Christophe Corvol, France

At the conclusion of this session, participants should be better able to:
1. Discuss the scientific basis for the placebo response and related effects
2. Recognize the nature and underpinnings of the placebo and nocebo responses
3. Apply the novel perspectives on the use of placebos in research and clinical practice

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4204 Parallel Session

Huntington’s Disease: From Bench to Bedside
15:00 – 17:00

Chairs: Sandrine Humbert, France
Karen Marder, USA

The Many Presentations of Huntington’s Disease and the Differential Diagnosis
Claudia Perandones, Argentina

The Role of Huntington in Neurodegeneration and Neurodevelopment: What Have We Learned?
Sandrine Humbert, France

Current and Future Therapies for Huntington’s Disease
Sarah Tabrizi, United Kingdom

CSPC Liaisons: Emilia Gatto, Argentina
Karen Marder, USA

At the conclusion of this session, participants should be better able to:
1. Recognize the many variable phenotypes of Huntington’s disease and potential differential diagnosis
2. Identify the genetic mechanisms underlying Huntington’s disease
3. Identify the current and new therapies for Huntington’s disease

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
### Wednesday, September 25, 2019

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Chairs</th>
<th>Liaison</th>
<th>Audience</th>
</tr>
</thead>
<tbody>
<tr>
<td>4205</td>
<td><strong>How to Diagnose Rare Movement Disorders</strong>&lt;br&gt;15:00 – 17:00</td>
<td>Pedro Garcia Ruiz, Spain&lt;br&gt;Emilia Gatto, Argentina</td>
<td>Shenyang Lim, Malaysia</td>
<td>Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees</td>
<td></td>
</tr>
<tr>
<td>4206</td>
<td><strong>Spasticity: From Bench to Bedside</strong>&lt;br&gt;15:00 – 17:00</td>
<td>Mark Hallett, USA&lt;br&gt;Raymond Rosales, Philippines</td>
<td>Buz Jinnah, USA</td>
<td>Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees</td>
<td></td>
</tr>
<tr>
<td>4207</td>
<td><strong>Translating Genetic Discoveries into Disease-Modifying Strategies for Parkinson’s Disease</strong>&lt;br&gt;15:00 – 17:00</td>
<td>Alexis Brice, France&lt;br&gt;Carolyn Sue, Australia</td>
<td>Vincenzo Bonifati, Netherlands</td>
<td>Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees</td>
<td></td>
</tr>
<tr>
<td>4208</td>
<td><strong>Dyskinesia in Parkinson’s Disease: From the Bedside to the Lab Bench</strong>&lt;br&gt;15:00 – 17:00</td>
<td>Angelo Antonini, Italy&lt;br&gt;Philippe Damier, France</td>
<td>Angela Cenci, Sweden</td>
<td>Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees</td>
<td></td>
</tr>
</tbody>
</table>
Wednesday, September 25, 2019

4309  Teaching Course

Recognition and Management of Non-Motor Symptoms in Parkinson’s Disease
15:00 – 17:00
Chairs: Bastiaan Bloem, Netherlands
K. Ray Chaudhuri, United Kingdom
Recognition and Management of Neuropsychiatric Disorders
Daniel Weintraub, USA
Recognition and Management of Dysautonomia
Alessandra Fanciulli, Austria
Recognition and Management of Pain and Fatigue
K. Ray Chaudhuri, United Kingdom

CSPC Liaison: Wassilios Meissner, France
At the conclusion of this session, participants should be better able to:
1. Describe the recognition and management of neuropsychiatric disorders in Parkinson’s disease
2. Summarize the recognition and management of dysautonomia in Parkinson’s disease
3. Discuss the recognition and management of pain and fatigue in Parkinson’s disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4310  Teaching Course

Palliative Care for Parkinson’s Disease
15:00 – 17:00
Chairs: Nicholas Galifianakis, USA
Victor McConvey, Australia
Definition and Models of Palliative Care
Stefan Lorenzl, Germany
Managing Palliative Needs of Patients and Their Caregivers
Nicholas Galifianakis, USA
End-of-Life Care
Miguel Coelho, Portugal

CSPC Liaison: Wassilios Meissner, France
At the conclusion of this session, participants should be better able to:
1. Define palliative care for Parkinson’s disease
2. Manage palliative needs of patients with Parkinson’s disease and their caregivers
3. Examine the management of end-of-life for Parkinson’s disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4411  Skills Workshop

Practical Use of the MDS-UPDRS
17:30 – 19:00
Evžen Růžička, Czech Republic
Glenn Stebbins, USA

CSPC Liaison: Christopher Goetz, USA
This interactive session will permit delegates to understand the core construct elements of the MDS-UPDRS, to practice application of the scale in a series of test cases, and to appreciate the process of establishing validated non-English editions. The session will be highly interactive between faculty and participants.

At the conclusion of this session, participants should be better able to:
1. Apply and interpret the scale in clinical and research settings
2. Practice using the MDS-UPDRS through interactive exercises and test cases during the session
3. Recognize the process utilized to develop validated non-English translations

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4412  Skills Workshop

Functional (Psychogenic) Movement Disorders
17:30 – 19:00
Isabel Parees, Spain
Jon Stone, United Kingdom

CSPC Liaison: Beomseok Jeon, South Korea
In this interactive session, the presenters will discuss how to effectively communicate about the diagnosis and management in patients with functional movement disorders. They will discuss novel/experimental treatments.

At the conclusion of this session, participants should be better able to:
1. Deliver an effective diagnostic explanation for functional movement disorders
2. Describe the approach for triaging patients for appropriate therapies
3. Interpret the nature of and role for novel/experimental treatments in functional movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4413  Skills Workshop

Neuromodulation for Movement Disorders: A Case-Based Approach
17:30 – 19:00
Jooji Jimenez-Shahed, USA
Frank Steigerwald, Germany

CSPC Liaison: Elena Moro, France
In this interactive session, the audience will be involved in the discussion of the selection and treatment of difficult movement disorders cases with neuromodulation therapies. Participants will be able to recognize and learn how to manage several types of complications and side effects in patients treated with neuromodulation.

At the conclusion of this session, participants should be better able to:
1. Identify common and uncommon issues in neuromodulation therapies
2. Manage side effects and complications related to neuromodulation therapies
3. Summarize the rational steps to optimize neuromodulation therapies

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Wednesday, September 25, 2019

4414  **Skills Workshop**  
**Botulinum Toxins: Difficult Cases and Pitfalls**  
17:30 – 19:00  
Austen Peter Moore, United Kingdom  
Raymond Rosales, Philippines  

CSPC Liaison: Roland Dominic Jamora, Philippines  

This interactive session will present potential pitfalls in the treatment of movement disorders with botulinum toxins, along with management strategies for problems that are more difficult to treat.  

At the conclusion of this session, participants should be better able to:  
1. Recognize potential pitfalls in the treatment of movement disorders with botulinum toxins  
2. Identify situations when botulinum toxin should not be used  
3. Analyze strategies to manage difficult cases and improve outcome in botulinum toxin use  

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

4515  **Video Session**  
**Lessons From My Patients**  
17:30 – 19:00  
Francisco Cardoso, Brazil  
Janet Rucker, USA  

CSPC Liaisons: Shengdi Chen, People's Republic of China  
Steven Frucht, USA  

In this interactive session, experienced faculty will describe some of the important lessons they have learned from their patients. The discussion will focus on misleading presentations in some cases, the complexity of individualizing care, and the role that patients sometimes play in reaching a correct diagnosis or treatment strategy.  

At the conclusion of this session, participants should be better able to:  
1. Recognize unusual and sometimes misleading presentations of movement disorders  
2. Discuss the complexity of delivering individualized patient care  
3. Describe the role patients play in educating their physicians  

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4516  **Video Session**  
**Video Demonstration of Pediatric Movement Disorders**  
17:30 – 19:00  
Miryam Carecchio, Italy  
Rose Pons, Greece  

CSPC Liaison: Maria Stamelou, Greece  

In this interactive session, the presenters will demonstrate with illustrative videos the wide phenotypic spectrum of pediatric movement disorders and their evolution into adulthood. The audience will also observe video cases of potentially treatable pediatric movement disorders that are important not to miss.  

At the conclusion of this session, participants should be better able to:  
1. Describe the phenotypic spectrum of movement disorders in children  
2. Recognize the evolution of pediatric movement disorders into adulthood  
3. Determine potentially treatable pediatric movement disorders  

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

4517  **Special Topics in Movement Disorders**  
**Sleep Disorders: REM Sleep Behavior Disorder**  
17:30 – 19:00  
Michael Howell, USA  
Michele Hu, United Kingdom  

CSPC Liaison: Claudia Trenkwalder, Germany  

In this interactive session the presenters will give insights into RBD symptoms, showing videos, defining the risk factors for prodromal Parkinson’s disease and discussing the future role of RBD for clinical trials, focused on the problems of conversion from RBD.  

At the conclusion of this session, participants should be better able to:  
1. Identify the clinical symptomatology of RBD and its assessment  
2. Illustrate the evolution of RBD into alpha-synucleinopathies  
3. Define the role of RBD for potential therapeutic trials  

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4518  **Special Topics in Movement Disorders**  
**Normal Pressure Hydrocephalus for Movement Disorders Neurologists**  
17:30 – 19:00  
Alfonso Fasano, Canada  
Joachim Krauss, Germany  

CSPC Liaison: Beomseok Jeon, South Korea  

In this interactive session, the presenters will discuss clinical features, diagnostic tools, surgery and their limitations in diagnosing and managing normal pressure hydrocephalus.  

At the conclusion of this session, participants should be better able to:  
1. Describe the clinical features and tools useful for diagnosis and differential diagnosis of normal pressure hydrocephalus  
2. Describe the heterogeneity and pathophysiological dilemmas of normal pressure hydrocephalus  
3. Select and inform possible surgical candidates for shunting  

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Thursday, September 26, 2019

5101  Themed Plenary Session

Synuclein in Parkinson’s Disease and Atypical Parkinsonism: From Bench to Bedside
8:00 – 9:30

Chairs:  Etienne Hirsch, France
Werner Poewe, Austria

Is Synucleinopathy a Single Entity?
Glenda Halliday, Australia

Pathogenic Spreading in the Synucleinopathies
Erwan Bezard, France

Clinical Trials in Synucleinopathies
Brit Mollenhauer, Germany

CSPC Liaison: Etienne Hirsch, France

At the conclusion of this session, participants should be better able to:
1. Analyze the clinical and pathological features of Parkinson’s disease and atypical parkinsonism
2. Debate the role of α-synuclein in the initiation and progression of Parkinson’s disease and atypical parkinsonism
3. Summarize new clinical trials for synucleinopathies

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

5102  Plenary Session

Controversies in Movement Disorders
10:00 – 11:00

Chairs:  Oscar Gershanik, Argentina
Antonio Strafella, Canada

Is There a Role for Cannabinoids in Movement Disorders?
(YES)
Benzi Kluger, USA

Is There a Role for Cannabinoids in Movement Disorders?
(NO)
Janis Miyasaki, Canada

Early Deep Brain Stimulation in Parkinson’s Disease?
(YES)
Patricia Limousin, United Kingdom

Early Deep Brain Stimulation in Parkinson’s Disease?
(NO)
Beomseok Jeon, South Korea

CSPC Liaison: Antonio Strafella, Canada

At the conclusion of this session, participants should be better able to:
1. Debate the advantages and disadvantages of cannabinoids in movement disorders
2. Debate the advantages and disadvantages of early Deep Brain Stimulation in Parkinson’s disease

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

5103  Plenary Session

Highlights for 2019: Looking Towards 2020
11:00 – 12:00

Chairs:  Vincenzo Bonifati, Netherlands
Christopher Goetz, USA

Basic Sciences
Etienne Hirsch, France

Clinical Sciences
Claudia Trenkwalder, Germany

CSPC Liaisons: Vincenzo Bonifati, Netherlands
Claudia Trenkwalder, Germany

At the conclusion of this session, participants should be better able to:
1. Critically review high impact scientific discoveries from the past year and important areas of scientific focus for 2020 research
2. Critically review high impact clinical studies from the past year and important ongoing trials with anticipated completion in 2020

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Non-CME Educational Activities

NEW! Science of Industry Session (non-CME)
These interactive sessions will provide delegates with a non-CME educational opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate basic scientists or clinicians working in industry, and topics may address the biological rationale or development process for specific therapeutics in development within the field of Movement Disorders.

Monday, September 23, 2019

2205 Science of Industry Session (non-CME) [TICKET]
Novel Treatment Strategies for Rare Movement Disorders
15:30 – 17:30
Chairs: David Devos, France
        Buz Jinnah, USA
PKAN: A Comparison of Multiple Potential Mechanisms and Treatment Strategies for Addressing the Biochemical Defect
Thomas Klopstock, Germany
GLUT1: A Comparison of Treatment Strategies for Bypassing the Glucose Transporter Defect
Emmanuel Roze, France
Reducing Brain Iron in Degenerative Disorders
Massimo Pandolfo, Belgium

CSPC Liaison: Buz Jinnah, USA
At the conclusion of this session, participants should be better able to:
1. Describe the biological rationale for new drugs being developed to address the underlying biochemical defect in pantothenatekinase-associated neurodegeneration
2. Compare the biological basis and clinical outcomes for different treatment strategies being used for GLUT1-related disorders
3. Summarize the biological rationale and clinical outcomes for treatment strategies focusing on reducing brain iron in movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

Tuesday, September 24, 2019

3208 Science of Industry Session (non-CME) [TICKET]
Translating Scientific Discovery into Novel Treatments for Movement Disorders
15:30 – 17:30
Chairs: Stanley Fahn, USA
        Buz Jinnah, USA
How Does Industry Decide Which Scientific Discoveries to Pursue?
Jesse Cedarbaum, USA
Targeting LRRK2 for Parkinson’s Disease
Carole Ho, USA
The Biology of Pathological Oscillations in the Brain: Potential Novel Targets for Tremor Disorders?
Margaret Lee, USA

CSPC Liaison: Buz Jinnah, USA
At the conclusion of this session, participants should be better able to:
1. Summarize the criteria used by industry to pursue clinical development of scientific discoveries
2. Describe the pathogenesis of LRRK2-related Parkinson’s disease and its rationale as a therapeutic target
3. Describe how understanding the biological basis for neuronal oscillations points to novel therapeutics for tremor disorders

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Faculty Listing

Tim Anderson, New Zealand  
3102

Mathieu Anheim, France  
3102

Angelo Antonini, Italy  
1102, 4208

Selma Aybek Rusca, Switzerland  
2208

Jean-Philippe Azulay, France  
2102

Peter Bain, United Kingdom  
3101

Fabrizio Benedetti, Italy  
4203

Daniela Berg, Germany  
1101

Erwan Bezard, France  
5101

Kailash Bhatia, United Kingdom  
3101

Roongroj Bhidayasiri, Thailand  
3516

Craig Blackstone, USA  
4206

Bastiaan Bloem, Netherlands  
4309

Vincenzo Bonifati, Netherlands  
3204, 5103

Alexis Brice, France  
4207

Helen Bronte-Stewart, USA  
2102

Francisco Cardoso, Brazil  
4515

Miryam Carecchio, Italy  
4516

Anna Castrioto, France  
3516

Jesse Cedarbaum, USA  
3208

M. Angela Cenci Nilsson, Sweden  
4208

K. Ray Chaudhuri, United Kingdom  
4309

Cynthia Comella, USA  
2101

Maria Fiorella Contarino, Netherlands  
2102

Mark Cookson, USA  
4207

Jean-Christophe Corvol, France  
3412, 4101

Esther Cubo Delgado, Spain  
2616

Philippe Damier, France  
4208

William Dauer, USA  
3206

Marina De Koning-Tijssen, Netherlands  
3205

Günter Deuschl, Germany  
3617

David Devos, France  
2205

Nico Diederich, Luxembourg  
3203

Bruno Dubois, France  
2203

Franck Durif, France  
1101

Alexandra Durr, France  
2206

Darius Ebrahimi-Fakhari, USA  
3310

Mark Edwards, United Kingdom  
2208

Carsten Eggers, Germany  
2309

Rodger Elble, USA  
3101

Terry Ellis, USA  
3411

Stewart Factor, USA  
MDS Video Challenge

Stanley Fahn, USA  
3208

Alessandra Fanciulli, Austria  
4309

Alfonso Fasano, Canada  
4618

Gilles Fenelon, France  
3203

Emilio Fernandez Alvarez, Spain  
3310

Joaquim Ferreira, Portugal  
4203

Susan Fox, Canada  
1101

Jennifer Friedman, USA  
2413

Steven Frucht, USA  
3102, 3205

Nicholas Galifianakis, USA  
4310

Ziv Gan-Or, Canada  
4207

Christos Ganos, Germany  
2207

Pedro Garcia Ruiz, Spain  
4205

Emilia Gatto, Argentina  
4205

Pierre Genton, France  
3205

Oscar Gershanik, Argentina  
4208, 5102

Nir Giladi, Israel  
1102

Christopher Goetz, USA  
2101, 4203, 5103

Lawrence Golbe, USA  
2204

Jennifer Goldman, USA  
1102, 2203

Mark Hallett, USA  
4206

Glenda Halliday, Australia  
5101

Clement Hamani, Canada  
2102

Andreas Hartmann, France  
2207

Rick Helmich, Netherlands  
3101

Tove Henriksen, Denmark  
2411

Etienne Hirsch, France  
5101, 5103
Faculty Listing

Carole Ho, USA
3208  
Jerome Honnorat, France
4102  
Michael Howell, USA
4617  
Michele Hu, United Kingdom
4617  
Sandrine Humbert, France
4204  
Sarosh Irani, United Kingdom
4102  
Klaus Jahn, Germany
2617  
Joseph Jankovic, USA
2515  
Beomseok Jeon, South Korea
2208, 5102  
Joohi Jimenez-Shahed, USA
4413  
Hyder Jinnah, USA
2205, 3208  
Ryuji Kaji, Japan
3206  
Han-Joon Kim, South Korea
2310, 3415  
Agnete Kirkeby, Denmark
2618  
Christine Klein, Germany
2101, 4207  
Thomas Klopstock, Germany
2205  
Benzi Kluger, USA
5102  
Joachim Krauss, Germany
4618  
Rejko Krueger, Luxembourg
4101  
Andrea Kuehn, Germany
2411  
Manju Kurian, United Kingdom
3310, MDS Video Challenge  
Kathrin LaFaver, USA
2208  
Vivek Lal, USA
3414  
Anthony Lang, Canada
MDS Video Challenge  
Jee-Young Lee, South Korea
2310  
Margaret Lee, USA
3208  
Stephane Lehericy, France
2310  
Simon Lewis, Australia
3203  
Shen-Yang Lim, Malaysia
1101  
Patricia Limousin, United Kingdom
5102  
Irene Litvan, USA
1103, 2204  
Stefan Lorenzl, Germany
4310  
Elan Louis, USA
1104  
Wim Mandemakers, Netherlands
2618  
Karen Marder, USA
4204  
Laura Marsh, USA
3203  
Davide Martino, Canada
2207  
Victor McConvey, Australia
4310  
Wassilios Meissner, France
3207  
Niccolo Mencacci, USA
3204  
Aurelie Meneret, France
3204  
Tiago Mestre, Canada
4203, MDS Video Challenge  
Janis Miyasaki, Canada
5102  
Hidehiro Mizusawa, Japan
2206  
Brit Mollenhauer, Germany
5101  
Austen Moore, United Kingdom
4414  
Francesca Morgante, United Kingdom
MDS Video Challenge  
Elena Moro, France
1102  
Huw Morris, United Kingdom
2204  
Alice Nieuwboer, Belgium
2309  
Jorik Nonnekes, Netherlands
2617  
Jill Ostrem, USA
3206  
Pramod Pal, India
4205  
Stéphane Palfi, France
2102  
Massimo Pandolfo, Belgium
2205  
Isabel Pareses, Spain
4412  
Martin Paucar Arce, Sweden
3413, MDS Video Challenge  
Maria Teresa Pellecchia, Italy
1103  
Claudia Perandones, Argentina
4204  
Maria Elisa Piemonte, Brazil
2309  
Sean Pittock, USA
4102  
Werner Poewe, Austria
5101  
Rose Pons, Greece
4516  
Ron Postuma, Canada
3309  
Olivier Rascol, France
1101, 4203  
Stephen Reich, USA
2204  
Irena Rektorova, Czech Republic
2203  
Gesime Respondek, Germany
2514  
Mayela Rodriguez Violante, Mexico
2309, 2413
Faculty Listing

Raymond Rosales, Philippines
4206, 4414

Emmanuel Roze, France
2205

Janet Rucker, USA
4515

Evžen Růžička, Czech Republic
4411

Ludger Schöels, Germany
2206

Michael Schwarzschild, USA
3207

Kapil Sethi, USA
MDS Video Challenge

Aasef Shaikh, USA
3414

Ali Shalash, Egypt
2616, 3310

Huifang Shang, People's Republic of China
2412

Hiroshi Shibasaki, Japan
3205

Andrew Siderowf, USA
4101

Tatyana Simuni, USA
3207

Friederike Sixel-Doring, Germany
4101

Elizabeth Slow, Canada
1104

Maria Stamelou, Greece
2204, 3101

Iva Stankovic, Serbia
2514

Glenn Stebbins, USA
4411

Frank Steigerwald, Germany
4413

Matthew Stern, USA
4101

Fabrizio Stocchi, Italy
3415

Jon Stone, United Kingdom
4412

Antonio Strafella, Canada
1104, 2203, 5102

Carolyn Sue, Australia
4102, 4207

D. James Surmeier, USA
3207

Matthis Synofzik, Germany
2412

Sarah Tabrizi, United Kingdom
4204

Louis Tan, Singapore
1102

Caroline Tanner, USA
3618

Helio Teive, Brazil
2206

Sue Thomas, United Kingdom
3411

Michele Tinazzi, Italy
3617

Francois Tison, France
1103

Masahiko Tomiyama, Japan
4208

Christine Tranchant, France
1104

Claudia Trenkwalder, Germany
2101, 5103

Enza Valente, Italy
3204

Martiie Van Egmond, Netherlands
3205

Thilo Van Eimeren, Germany
2310

Charles Venuto, USA
3412

Marie Vidailhet, France
1104, 3206

Aleksandar Videnovic, USA
3309

Angela Vincent, United Kingdom
4102

Daniel Weintraub, USA
4309

Gregor Wenning, Austria
1103

Ana Westenberger, Germany
3413

Caroline Williams-Gray, United Kingdom
2203

Juliane Winkelmann, Germany
3309

Joerg Wissel, Germany
4206

Yulia Worbe, France
2207
CME Information

Target Audience
Clinicians, researchers, post-doctoral fellows, medical residents, medical students, allied health professionals with an interest in current clinical trends and approaches for diagnosis and treatment of movement disorders.

Objectives
1) Evaluate the pharmacological and non-pharmacological management options available for Parkinson’s disease and other movement disorders
2) Discuss the diagnostic approaches and tools available for Parkinson’s disease and other movement disorders
3) Describe the pathogenesis and neurobiology of Parkinson’s disease and other movement disorders

Satisfactory Completion
Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.

Accreditation Statement
The International Parkinson and Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

Credit Designation Statement
The International Parkinson and Movement Disorder Society designates this live activity for a maximum of 33.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgements

Platinum Plus Level

Platinum Level

Bronze Level

Ipsen Innovation

The International Congress of Parkinson’s Disease and Movement Disorders Scientific Program is supported through an unrestricted medical education grant from Ipsen Innovation.
INCISIONLESS, MR-GUIDED FOCUSED ULTRASOUND THALAMOTOMY FOR ESSENTIAL TREMOR & TREMOR-DOMINANT PARKINSON’S DISEASE

• Immediate improvement in tremor
• Sub-millimeter target movement
• Real-time, physiologic feedback to optimize treatment
• Safe & effective with minimal side effects

www.insightec.com | www.essential-tremor.com


Safety Information: https://www.insightec.com/us/safety-information

Product Name: Exablate Neuro

PUB41003838 Rev. 1
GUIDE XT is DBS Visualization Software that provides the ability to see implanted leads and Stimulation Field Models (SFM)s in the patient’s own segmented anatomy.
MAKE A
PARKINSON’S HOUSE CALL

Visit the Sunovion Booth
for an immersive and interactive exhibit that illustrates life with Parkinson’s disease and the types of OFF episodes that patients experience.
Unleash your DBS programming potential with the intuitive, insightful, secure Clinician Programmer.

Our clinician programmer makes a smarter journey possible with next-generation programming technology designed to build trust and confidence. With an intuitive interface, secure wireless connection, and streamlined access to patient data — you’ll have all the support you need along the way.

Visit our booth to learn more about the DBS Clinician Programmer.

medtronic.com/dbstherapy

A prescription is required. Not everyone who receives DBS Therapy will receive the same results. DBS Therapy requires brain surgery which can have serious and sometimes fatal complications. Once implanted, DBS complications may require additional surgery. Medtronic DBS Therapy may cause new or worsening neurological or psychiatric symptoms. Patients should always discuss the potential risks and benefits of the therapy with a physician.

©2018 Medtronic UC201901991a EN
Biogen invites you to join an engaging panel discussion on progressive supranuclear palsy (PSP).

Differentiating PSP

Monday, September 23, 2019
12:45 PM–1:45 PM
Nice Acropolis Convention Centre
Nice, France
A symposium at the International Congress of Parkinson’s Disease and Movement Disorders, Nice, France

BEYOND MOTOR WEARING-OFF:

WHAT ARE WE MISSING?

Monday 23rd September
12:45-13:45

Professor Olivier Rascol
TOULOUSE, FRANCE
Chairman’s introduction

Dr Mark Stacy
GREENVILLE, USA
The spectrum of OFF

Professor Per Odin
LUND, SWEDEN
The time course of non-motor complications

Professor Joaquim Ferreira
LISBON, PORTUGAL
The time course of motor complications

This symposium is organised and fully sponsored by BIAL